Clinical Trial Detail

NCT ID NCT01776723
Title A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute|Incyte Corporation
Indications

chronic myeloid leukemia

Therapies

Ruxolitinib

Age Groups: adult

No variant requirements are available.